Maravai LifeSciences Holdings, Inc.
MRVINASDAQHealthcare● Active
$5.10
+$0.08(+1.49%)
Market Cap$1.4B
P/E Ratio—
52W High$5.19
52W Low$1.99
Maravai LifeSciences Holdings, Inc. (MRVI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MRVI · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.19B | $0.26B | $0.29B | $0.88B | $0.80B |
| Cost of Revenue | $0.15B | $0.15B | $0.15B | $0.17B | $0.14B |
| Gross Profit | $0.03B | $0.11B | $0.14B | $0.71B | $0.66B |
| Gross Margin %(computed) | 17.98% | 41.79% | 48.52% | 80.87% | 82.41% |
| Operating Expenses | |||||
| R&D Expenses | $0.02B | $0.02B | $0.02B | $0.02B | $0.02B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.04B | $0.34B | $0.17B | $0.14B | $0.10B |
| Operating Income | ($0.01B) | ($0.24B) | ($0.03B) | $0.57B | $0.55B |
| Operating Margin %(computed) | -3.63% | -90.91% | -10.95% | 65.03% | 69.40% |
| Interest Income | $0.02B | $0.03B | $0.03B | $0.00B | $0.00B |
| Interest Expense | $0.03B | $0.05B | $0.05B | $0.02B | $0.03B |
| Income Before Tax | ($0.23B) | ($0.26B) | $0.62B | $0.55B | $0.53B |
| Income Tax Expense | ($0.00B) | ($0.00B) | $0.76B | $0.06B | $0.06B |
| Net Income | ($0.13B) | ($0.14B) | ($0.12B) | $0.22B | $0.18B |
| Net Margin %(computed) | -70.41% | -55.89% | -41.19% | 24.94% | 22.78% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.91 | $-1.05 | $-0.90 | $1.67 | $1.59 |
| Wtd Avg Shares | 0.15B | 0.14B | 0.13B | 0.13B | 0.11B |
| EBITDA | ($0.15B) | ($0.16B) | $0.71B | $0.61B | $0.59B |
| EBITDA Margin %(computed) | -79.20% | -60.54% | 246.56% | 69.08% | 73.29% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Maravai LifeSciences Holdings, Inc. data
About Maravai LifeSciences Holdings, Inc. (MRVI) Income Statement
Maravai LifeSciences Holdings, Inc. (MRVI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MRVI reported revenue of $0.19B, gross profit of $0.03B (gross margin 17.98%), and net income of ($0.13B) — a net profit margin of -70.41%.
Frequently asked questions
MRVI · 4 questionsMaravai LifeSciences Holdings, Inc. (MRVI) reported revenue of $0.19B for 2025, down 28.3% year-over-year.
MRVI revenueMRVI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08